Cingulate Inc (CING) AI Stock Analysis

• Market Cap: $27.64M
• Dividend Yield: N/A
• Average Volume (3M): 110.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 4.99
• Revenue Growth: N/A
• EPS Growth: 95.52%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 5,146,239
• 10 Day Avg. Volume: 138,656
• 30 Day Avg. Volume: 110,218
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -342.56
• Enterprise Value/Revenue: 1.23
• Enterprise Value/Gross Profit: 1.46
• Enterprise Value/Ebitda: 155.35
• 1Y Price Target: $25.00
• Price Target Upside: 365.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 47 Neutral
• Price Target: ―

Cingulate Inc.'s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.

Positive Factors

Market Potential

Considering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.

Product Efficacy

Cingulate's CTx-1301 demonstrated potential best-in-class onset and duration for ADHD, making it a competitive differentiator amidst ongoing stimulant shortages.

Regulatory Progress

FDA suggests Cingulate may file NDA for CTx-1301 with existing data, indicating sufficient data is already available for submission.

Negative Factors

Financial Performance

Cingulate reported a net loss of $6.1M for the fourth quarter and $15.5M for the year, which could be a concern for investors.

Operating Expenses

Operating expenses in the fourth quarter were significantly higher than expected, potentially affecting financial performance.

Statistical Significance

Despite achieving clinical meaningfulness, the Phase 3 study did not achieve statistical significance as it was not powered for this objective.

Cingulate Inc Business Overview & Revenue Model

Company Description

Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for the treatment of central nervous system disorders. Operating primarily in the healthcare and pharmaceutical sectors, the company is dedicated to addressing unmet medical needs through its portfolio of proprietary drug candidates, with a particular emphasis on attention deficit/hyperactivity disorder (ADHD) and anxiety disorders.

How the Company Makes Money

Cingulate Inc. generates revenue through the research, development, and eventual commercialization of its proprietary drug formulations. The company focuses on advancing its product candidates through clinical trials and obtaining regulatory approvals, which would enable them to market these drugs to healthcare providers and patients. Revenue streams are expected to include sales of approved medications, licensing agreements, and potential partnerships with other pharmaceutical companies. Additionally, Cingulate may engage in collaborative research arrangements that provide funding and milestone payments, contributing to its financial inflows.

Cingulate Inc Financial Statement Overview

Summary

Cingulate Inc. faces significant financial challenges with no revenue, persistent losses, and negative cash flows. The lack of debt is a positive aspect, but zero equity and dependency on external funding highlight financial instability.

Income Statement

Cingulate Inc. has consistently reported zero revenue across the years, indicating no sales or commercialization activities. The company is experiencing significant losses, with negative EBIT and Net Income frequently worsening year over year. There is no revenue growth, and both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and financial distress.

Balance Sheet

The company has no debt as of the latest report, which is a positive aspect. However, the stockholders' equity is zero, indicating a lack of financial cushion. Historical data shows negative equity in some years, highlighting financial instability. The absence of liabilities may be misleading due to the lack of assets compared to the company’s size and industry norms.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn without revenue generation. The free cash flow is also negative, indicating that the company is not generating sufficient cash to cover its operational needs. There is no growth in free cash flow, and the heavy reliance on financing cash flow suggests dependency on external funding to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-582.92K	-621.99K	-808.44K	-842.35K
EBITDA	-15.64M	-22.95M	-17.05M	-19.87M	-6.29M
Net Income	-15.55M	-23.53M	-17.85M	-20.74M	-7.28M
Balance Sheet
Total Assets	14.86M	3.49M	11.41M	22.89M	5.79M
Cash, Cash Equivalents and Short-Term Investments	12.21M	52.42K	5.36M	16.49M	1.20M
Total Debt	5.10M	3.14M	5.53M	881.13K	2.05M
Total Liabilities	7.41M	10.36M	7.52M	2.04M	4.50M
Stockholders Equity	7.46M	-6.87M	-69.41M	20.84M	1.29M
Cash Flow
Free Cash Flow	-18.66M	―	-16.04M	-11.25M	-7.21M
Operating Cash Flow	-18.45M	-15.03M	-15.88M	-10.43M	-6.81M
Investing Cash Flow	-211.80K	-224.00K	-152.65K	-814.74K	-384.17K
Financing Cash Flow	30.82M	9.96M	4.90M	26.54M	7.97M

Cingulate Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Positive. The current price of 5.37 is above the 20-day moving average (MA) of 4.67, above the 50-day MA of 4.32, and above the 200-day MA of 4.31, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 64.67 is Neutral, neither overbought nor oversold. The STOCH value of 73.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CING.

Cingulate Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
CING	47 Neutral	$27.64M	―	-358.06%	―	―	95.52%
CARM	46 Neutral	$16.48M	―	-362.79%	―	32.45%	39.31%
PHGE	44 Neutral	$11.47M	―	-68.18%	―	―	45.24%
HOOK	37 Underperform	$11.87M	―	-105.79%	―	-82.54%	-12.53%
NXTC	36 Underperform	$14.08M	―	-63.94%	―	―	22.63%

Cingulate Inc Corporate Events

Cingulate Inc Secures $3M Grant for Anxiety Drug

On April 8, 2025, Cingulate Inc. entered into a Grant Agreement with a private foundation to receive a $3 million grant for the development of CTx-2103, a once-daily formulation of buspirone for anxiety treatment. This funding, distributed in three $1 million payments, will accelerate Cingulate’s pipeline and validate its PTR technology, potentially reducing reliance on benzodiazepines and addressing a significant market need in the $5.5 billion U.S. anxiety market.

Spark’s Take on CING Stock

According to Spark, TipRanks’ AI Analyst, CING is a Neutral.

Cingulate Inc.’s stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, including progress towards FDA approval for CTx-1301, provide a significant positive outlook. Technical indicators show neutral market momentum, but valuation remains a concern due to financial losses and lack of dividends.

To see Spark’s full report on CING stock, click here.

Cingulate Inc. Advances Towards FDA Approval for CTx-1301

On March 4, 2025, Cingulate Inc. announced the safety results from its final Phase 3 trials for CTx-1301, a novel, once-daily stimulant medication for ADHD, which showed no serious adverse events and consistent safety profiles. The results, submitted to the FDA ahead of an April 2 meeting, mark a significant step towards filing for FDA approval mid-2025, potentially positioning Cingulate as a leader in ADHD treatment with a product that addresses unmet needs in the market.